Anlotinib plus chemotherapy for T790M-negative EGFR-mutant non-sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial.

Juan LiYuke TianMin ZhengJun GeJiliang ZhangDejun KongMei ChenPing Yu

Published in: Thoracic cancer (2022)

Anlotinib plus platinum and pemetrexed showed promising antitumor activity with manageable toxicity in patients with T790M-negative EGFR-mutant advanced nonsquamous NSCLC after progression on first- or second-generation EGFR TKIs.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
brain metastases
wild type
oxidative stress
clinical trial
study protocol
locally advanced
phase iii
radiation therapy